{"id":390050,"date":"2021-04-05T00:00:00","date_gmt":"2021-04-05T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0010-2020-biopharma-diabetic-nephropathy-disease-landscape-and-forecast-g7-2020\/"},"modified":"2026-03-31T10:43:33","modified_gmt":"2026-03-31T10:43:33","slug":"dlsfmd0010-2020-biopharma-diabetic-nephropathy-disease-landscape-and-forecast-g7-2020","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0010-2020-biopharma-diabetic-nephropathy-disease-landscape-and-forecast-g7-2020\/","title":{"rendered":"Diabetic Nephropathy | Disease Landscape and Forecast | G7 | 2020"},"content":{"rendered":"<p>Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. The current standard of care fails to halt the frequent progression of DN to kidney disease and, ultimately, kidney failure\u2014a condition associated with severe morbidity \/ mortality and high costs to patients and payers. As a result, key opinion leaders (KOLs) indicate that efficacious therapies for DN are a major unmet need. KOLs weigh in on the anticipated nephroprotective effects that endothelin receptor antagonists, mineralocorticoid receptor antagonists, and SGLT-2 inhibitors may offer. These therapies represent the first potentially disease-modifying therapies, should they prove efficacious and safe. The increasing prevalence of DN, exacerbated by the dynamics between clinicians seeking to prescribe new, premium-priced therapies and payers seeking to control costs among an already expensive population, will help shape the changing DN market over the next ten years.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul>\n<li>Will the inclusion of cardiovascular endpoints in the clinical trials for select therapies be a competitive advantage once commercially available?<\/li>\n<li>How do KOLs view the different mechanisms of action of the therapies in early- and late-phase clinical development?<\/li>\n<li>What are the key remaining unmet needs in DN? Which drugs in development will fulfill these unmet needs?<\/li>\n<li>What market access and reimbursement challenges will the emerging therapies face in the G7? How will these challenges influence their uptake?<\/li>\n<\/ul>\n<p><em>Disease Landscape &#038; Forecast: <\/em>Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390050","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-diabetic-nephropathy","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390050","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390050\/revisions"}],"predecessor-version":[{"id":576419,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390050\/revisions\/576419"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390050"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}